Publications by authors named "Katarzyna Poniewierska-Jasak"
High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group.
Iwona Hus Joanna Mańko Dariusz Jawniak Artur Jurczyszyn Grzegorz Charliński Katarzyna Poniewierska-Jasak
Oncol Lett
December 2019
Article Synopsis
- - The study assessed the effectiveness and safety of the VTD treatment (bortezomib, thalidomide, dexamethasone) in 205 newly diagnosed multiple myeloma patients preparing for autologous stem cell transplantation.
- - Results showed high response rates, with 94.6% achieving at least a partial response and 67.8% reaching at least a very good partial response after a median of 6 treatment cycles.
- - While peripheral neuropathy was a concern for 28.7% of patients, the therapy was generally well tolerated and did not hinder stem cell collection or recovery after transplantation.
Introduction: Significant and accessible predictive factors for bortezomib treatment in plasma cell myeloma (PCM) are still lacking. TP53 codon 72 polymorphism (P72R) results in proline (P) or arginine (R) at 72 amino acid position, which causes synthesis of proteins with distinct functions. The aims of our study were to: 1) analyze whether this polymorphism is associated with an increased risk of PCM; 2) study whether the P72R polymorphism affects overall survival (OS) among PCM patients; 3) assess the possible association of the P72R polymorphism with sensitivity to bortezomib in cell cultures derived from PCM patients.
View Article and Find Full Text PDF